Complete Scientific Guide to Omega-3 Fatty Acids: Evidence, Safety, and Use

Few nutrients attract as much praise, controversy, and marketing as omega-3 fatty acids. In one decade a headline calls them a heart-saving miracle, and in the next a large trial finds no benefit. Both stories are partly true, because the answer depends on which omega-3, which dose, which person, and which outcome. This guide is a complete, plain-language scientific reference to omega-3 fatty acids. It covers EPA and DHA, the plant-based ALA, how fish oil and other omega-3 supplements are made, how they work in the body, what clinical trials actually show, and how to judge safety and quality.

Every claim is tied to the strength of its evidence, so you can separate what is established from what is merely promising. If you are a consumer, a clinician, or a researcher, use the sections below as a map, and jump to the ones that matter most to you.

Omega-3 Fatty Acids Quick Facts and Executive Summary

The table gives the essentials at a glance, and the paragraphs after it summarize the whole guide.

Item	Quick fact
Family	Polyunsaturated fatty acids (PUFAs) of the n-3 series
Main members	ALA (18:3n-3), EPA (20:5n-3), DPA (22:5n-3), DHA (22:6n-3)
Essential nutrient	ALA is essential; EPA and DHA can be made from ALA only in small amounts
Main dietary sources	Oily fish, fish oil, cod liver oil, krill oil, algal oil; ALA from flaxseed, chia, walnuts, and canola
Common supplement dose	About 250 to 1,000 mg of combined EPA and DHA per day
Prescription dose	2 to 4 g per day for severe hypertriglyceridemia (triglycerides of 500 mg/dL or higher)
Best-supported effect	Lowering of blood triglycerides
Mixed evidence	Prevention of heart attacks and strokes in the general population
Main cautions	Bleeding at high doses, atrial fibrillation at higher doses, oxidized products, fish or shellfish allergy
Regulation	Sold as foods and supplements in most regions; high-dose forms exist as approved prescription drugs

In summary, omega-3 fatty acids are structural fats that become part of every cell membrane, and they act as raw material for signaling molecules that influence inflammation, blood clotting, and nerve function. Their strongest and most consistent clinical effect is lowering triglycerides. For heart disease, results depend heavily on the dose and the population: a high-dose, purified EPA product reduced events in one major trial of high-risk patients, while several trials of mixed EPA and DHA at lower doses found little or no benefit. Evidence for pregnancy outcomes, rheumatoid arthritis, and depression is promising but less certain. Safety at typical doses is good, but higher doses carry a documented signal for atrial fibrillation, and product quality varies widely. The rest of this page explains how we know what we know.

Most public health bodies suggest roughly 250 to 500 mg of combined EPA and DHA per day for healthy adults, which equals about two servings of oily fish per week. No official recommended daily allowance exists for EPA and DHA, although an adequate intake exists for ALA (1.6 g per day for men and 1.1 g per day for women in the United States).

What Are Omega-3 Fatty Acids? Definition and Identity

Omega-3 fatty acids are a family of long, unsaturated fats that share one structural feature: the first double bond sits three carbons away from the methyl (omega) end of the carbon chain. The name "omega-3" or "n-3" simply describes that position. Because the double bonds are in the cis configuration and separated by single carbon spacers, the chains are bent and flexible, which is one reason they make cell membranes more fluid.

Three members dominate nutrition science. ALA (alpha-linolenic acid) has 18 carbons and three double bonds, and it is found mainly in plants. EPA (eicosapentaenoic acid) has 20 carbons and five double bonds. DHA (docosahexaenoic acid) has 22 carbons and six double bonds. EPA and DHA are called long-chain omega-3s, and they are the forms most often studied in clinical trials. A fourth form, DPA (docosapentaenoic acid), appears in smaller amounts in seafood and in the human body.

Humans lack the enzyme needed to insert a double bond at the n-3 position, so we cannot build omega-3 fatty acids from scratch. This is why ALA is classified as an essential fatty acid, which must come from food. The body can lengthen and desaturate ALA into EPA and DHA, but the conversion is inefficient, usually in the range of a few percent for EPA and often below that for DHA. For this reason, many experts consider EPA and DHA conditionally essential, especially during pregnancy, infancy, and in people who eat no fish.

Omega-3 fatty acids work alongside omega-6 fatty acids such as linoleic acid. The two families compete for the same enzymes, and both are needed. Modern Western diets contain far more omega-6 than omega-3, but the idea that a precise ratio is critical is not strongly supported by trials. The absolute intake of EPA and DHA appears to matter more.

Chemical Classification of Omega-3 Fatty Acids

Omega-3s are lipids, specifically straight-chain, polyunsaturated, carboxylic acid fatty acids. The scientific shorthand describes the number of carbons, the number of double bonds, and the position of the first double bond, so EPA is written 20:5n-3 and DHA 22:6n-3.

Fatty acid	Common abbreviation	Carbons : double bonds	Typical origin
Alpha-linolenic acid	ALA	18:3n-3	Flaxseed, chia, walnuts, canola, perilla
Stearidonic acid	SDA	18:4n-3	Hemp seed, echium, some engineered crops
Eicosapentaenoic acid	EPA	20:5n-3	Fish, krill, microalgae
Docosapentaenoic acid	DPA	22:5n-3	Fish, seal oil, human tissues
Docosahexaenoic acid	DHA	22:6n-3	Fish, krill, microalgae

Because omega-3s occur in many chemical forms, classification also includes how the fatty acid is attached to other molecules. In nature, most are bound in triglycerides (three fatty acids on a glycerol backbone) or phospholipids (two fatty acids and a phosphate head group, as in krill oil and fish roe). In commercial concentrates, they are often converted into ethyl esters, and some products are then rebuilt into re-esterified triglycerides. A smaller group is sold as free fatty acids. These distinctions matter because the form influences absorption, stability, and cost, which we discuss in later sections.

Unlike many ingredients, omega-3 is not a single botanical or animal species. It is a chemical family found in plants, algae, and animals. Strictly speaking, the "classification" of an omega-3 product depends on its source organism, such as Engraulis ringens (Peruvian anchoveta), Euphausia superba (Antarctic krill), or Schizochytrium species (microalgae), and on its chemical form.

Origin, Cultivation, and Sources of EPA and DHA

A common misconception is that fish make omega-3s. Most do not. The original producers of EPA and DHA are microalgae and other single-celled marine organisms. Small animals such as zooplankton and krill eat them, small fish eat the zooplankton, and larger fish accumulate the fats along the food chain. This explains why cold-water oily fish such as salmon, mackerel, herring, sardines, and anchovies are rich in omega-3, and why lean fish such as cod store most of their omega-3 in the liver.

Wild-caught fish oil. Most commercial fish oil comes from small, fast-growing forage fish, including anchovies, sardines, and menhaden, and from the byproducts of fish processing. Peru and Chile supply a large share of the world's raw material through the anchoveta fishery. Fish stocks vary with ocean conditions, so supply and price fluctuate.

Farmed fish. Fish raised in aquaculture only contain as much EPA and DHA as their feed provides. As feed makers have replaced fish oil with plant oils to reduce costs, the omega-3 content of some farmed salmon has declined over the years, although it often remains higher than most other foods.

Krill. Antarctic krill are harvested in the Southern Ocean under a conservation commission that sets catch limits. Krill oil carries omega-3s mainly in phospholipid form, with a natural reddish color from the carotenoid astaxanthin.

Algal oil. Microalgae such as Schizochytrium and Crypthecodinium cohnii are grown in closed fermentation tanks to produce DHA, and Nannochloropsis has been used for EPA. Algal oil is free of ocean-borne pollutants and suitable for vegans, and it is the most direct route to long-chain omega-3.

Plant sources. Flaxseed (Linum usitatissimum), chia (Salvia hispanica), perilla, hemp, walnuts, and canola provide ALA only. Crops engineered to produce EPA and DHA, such as certain canola and camelina lines, have been developed and are being commercialized in some markets.

Sustainability is a growing concern. Buyers can look for third-party certifications for wild fisheries and for responsible krill harvests, and algal oil offers an alternative that does not depend on ocean stocks.

History and Traditional Use of Fish Oil

Fish oil is among the oldest dietary supplements. Coastal communities in northern Europe used cod liver oil for centuries, and by the nineteenth century physicians prescribed it for rickets and joint complaints. Its benefits for rickets were later traced mainly to vitamin D rather than to omega-3s, a reminder that traditional use does not prove which compound is responsible.

The scientific history of omega-3 began in 1929 and 1930, when George and Mildred Burr showed that rats fed fat-free diets developed deficiency disease that could be cured by certain unsaturated fats, which established the concept of essential fatty acids. The specific need for omega-3 in humans was recognized much later. In 1982, Holman and colleagues described a young patient receiving intravenous nutrition who developed neurological symptoms that resolved when ALA was added, which was an early demonstration of human omega-3 deficiency.

The modern surge of interest came from epidemiology in the 1970s. Danish researchers Bang and Dyerberg reported that Greenland Inuit populations eating large amounts of marine animals had low rates of heart attack, and they linked this to high intake of EPA. This hypothesis inspired decades of research, although later reviews have questioned how much of the Inuit pattern was due to omega-3 alone (Fodor et al., 2014). The first major randomized trial, the Diet and Reinfarction Trial published in 1989, found fewer deaths in men with a heart attack history who were advised to eat fatty fish (Burr et al., 1989). The Italian GISSI-Prevenzione trial in 1999 added support for a small benefit of a daily omega-3 capsule after myocardial infarction (GISSI-Prevenzione Investigators, 1999).

These early results set high expectations, and the following twenty years of larger trials produced a more complex picture, which we cover in the clinical evidence sections.

Modern Nutraceutical Use of Omega-3 Supplements

Today omega-3 supplements are among the most commonly used dietary supplements in several countries. Consumers take them for heart health, brain and eye health, joint comfort, mood, pregnancy support, skin, and general wellness. The industry includes capsule and liquid fish oil, krill oil, algal oil, flaxseed oil, fortified foods such as eggs and milk, infant formula with added DHA, and medical foods.

Prescription omega-3 products form a separate class. Omega-3-acid ethyl esters (Lovaza) were approved in the United States in 2004 for severe hypertriglyceridemia, and icosapent ethyl (Vascepa), a purified EPA ethyl ester, was approved in 2012 for the same purpose and in 2019 for reducing cardiovascular events in selected high-risk patients on statins. These products are manufactured to pharmaceutical standards and are used at 2 to 4 grams per day under medical supervision.

In clinical nutrition, omega-3 is also used in parenteral nutrition lipid emulsions and in specialized enteral formulas. In sports nutrition, researchers have examined its role in muscle recovery and soreness, with modest and inconsistent findings. In pet and animal nutrition, omega-3 is added to feeds to improve coat condition and to enrich eggs and meat.

An important point for readers is that the term "omega-3 supplements" covers very different products. A 1,000 mg fish oil softgel may contain only 300 mg of EPA and DHA, while a prescription capsule may deliver almost 1,000 mg of a single purified EPA ester. A fair evaluation of the science always begins with the actual EPA and DHA content, not the total oil weight.

Chemical Composition of Omega-3 Oils

Omega-3 oils are mixtures, and their fatty acid profile differs by source and by processing. The approximate ranges below are typical, and individual products vary widely.

Oil	Main omega-3 content	Typical profile notes
Standard fish oil (anchovy, sardine)	About 30 percent EPA and DHA combined	Roughly 18 percent EPA and 12 percent DHA in a common 18:12 grade
Concentrated fish oil	50 to 90 percent EPA and DHA	Made by distillation or other concentration methods
Cod liver oil	About 15 to 20 percent EPA and DHA	Also contains vitamins A and D
Krill oil	Roughly 15 to 30 percent EPA and DHA	Mainly phospholipids; contains astaxanthin
Algal oil	Often 35 to 50 percent DHA, sometimes with EPA	Vegan source of long-chain omega-3
Flaxseed oil	About 50 to 55 percent ALA	No EPA or DHA
Chia and perilla oil	About 55 to 65 percent ALA	No EPA or DHA

Beyond the fatty acids themselves, oils contain minor components. Natural fish oils contain small amounts of cholesterol, fat-soluble vitamins, and, if poorly refined, contaminants. Manufacturers add antioxidants such as mixed tocopherols (vitamin E) or rosemary extract because polyunsaturated fats oxidize easily. Softgel shells are usually made from gelatin or, in vegetarian products, from starch or carrageenan. Flavorings such as lemon or orange oil may be added to hide the taste.

The number of double bonds explains the stability problem: each double bond is a site that oxygen can attack, so DHA with six double bonds is more fragile than ALA with three. Light, heat, and air speed the damage, and oxidized oil develops rancid odors, reduced potency, and potentially harmful breakdown products.

Key Active Compounds: EPA, DHA, ALA, and Their Metabolites

The active compounds in omega-3 products fall into three groups: the parent fatty acids, the molecules the body makes from them, and the companion nutrients in the oil.

EPA and DHA. These two fatty acids deliver most of the biological effects observed in trials. EPA is rich in cardiovascular and inflammatory research, and DHA is concentrated in the brain and retina. They are not interchangeable, and some trials suggest different effects on lipids. For example, DHA-containing products tend to raise LDL cholesterol slightly, while pure EPA products usually do not.

ALA. This plant fatty acid is a modest source of EPA and DHA after conversion, and it may have its own benefits for heart health, although the evidence is weaker than for marine omega-3s.

DPA. An intermediate between EPA and DHA, DPA is under investigation for its own effects on platelets and inflammation.

Lipid mediators. The body converts EPA and DHA into oxygenated metabolites collectively called oxylipins. Among them, the specialized pro-resolving mediators, including resolvins, protectins, and maresins, help to terminate inflammation and promote tissue repair. EPA also forms 3-series prostaglandins and thromboxanes and 5-series leukotrienes, which are generally less inflammatory than the equivalent compounds made from the omega-6 fatty acid arachidonic acid. Their measurement in humans remains technically difficult, so their exact role in the clinical effects of supplements is still debated.

Companion compounds. Depending on the oil, products may also contain vitamins A and D (cod liver oil), astaxanthin (krill oil), phospholipid-bound choline, and added vitamin E. These are important when evaluating total vitamin intake and possible interactions.

Extraction and Processing of Fish Oil and Other Omega-3 Oils

Processing determines purity, taste, stability, and the EPA and DHA concentration. Most fish oil production follows these stages.

1. Raw material handling. Fish or trimmings are processed quickly after catch, since fats start to degrade when the fish is warm or stored for long periods.
2. Crude oil recovery. The material is cooked, pressed, and centrifuged, which separates the oil from the water and protein (fish meal).
3. Refining. Crude oil is degummed to remove phospholipids, neutralized to remove free fatty acids, bleached with clay to remove pigments and some contaminants, and deodorized with steam under vacuum to remove odor compounds.
4. Winterization. Cooling the oil removes saturated fats that would otherwise cloud the product.
5. Concentration. To raise the EPA and DHA content, producers convert the triglycerides to ethyl esters with ethanol, then use molecular (short-path) distillation, urea complexation, chromatography, or supercritical carbon dioxide to enrich the long-chain omega-3. Some producers then use enzymes to rebuild the esters into triglycerides, giving a re-esterified triglyceride form.
6. Stabilization and packaging. Antioxidants are added, and the oil is protected with nitrogen and packed in light-protected containers.

Molecular distillation also helps to lower environmental pollutants such as dioxins, PCBs, and mercury, which are mostly removed during refining and concentration.

Krill oil is typically extracted from frozen or freshly processed krill using ethanol, acetone, or other solvents, or with enzymes, and the product keeps a naturally phospholipid-rich structure. Algal oil comes from fermentation, followed by cell disruption and extraction with solvents or by mechanical or enzymatic methods, then refining. Flaxseed oil is usually cold-pressed, because heat damages ALA, and it is best stored refrigerated in dark glass.

Standardization and Potency of Omega-3 Supplements

Because omega-3 oils are mixtures, potency has to be defined carefully. The most important number on any label is the amount of EPA and DHA per serving, not the total oil per capsule. A softgel marked "1,000 mg fish oil" may contain only about 300 mg of EPA and DHA, while a concentrated product of the same size may deliver 600 mg or more. When comparing omega-3 supplements, divide the price by the milligrams of EPA and DHA, not by the number of capsules.

Several measures describe quality and potency:

• EPA and DHA content (mg per serving): Required on well-made labels and the basis for dose comparisons across studies.
• Chemical form: Triglyceride, ethyl ester, re-esterified triglyceride, phospholipid, or free fatty acid.
• Oxidation markers: The peroxide value (PV) measures primary oxidation, and the anisidine value (AV) measures secondary oxidation. Together they give the TOTOX value, calculated as two times PV plus AV. The voluntary monograph of the Global Organization for EPA and DHA Omega-3s (GOED) sets limits of 5 meq/kg for PV, 20 for AV, and 26 for TOTOX.
• Contaminant limits: Voluntary and pharmacopeial standards set maximum levels for heavy metals, PCBs, dioxins, and polycyclic aromatic hydrocarbons.

There is also a way to standardize potency inside the body. The Omega-3 Index is the percentage of EPA plus DHA in red blood cell membranes, measured as a share of total fatty acids. Researchers proposed that an index of 8 percent or higher is associated with the lowest cardiovascular risk, while 4 percent or lower is the least favorable (Harris and von Schacky, 2004). This is a research and practice tool, and trials have not yet proven that raising the index to a target improves outcomes. Still, it offers a useful way to account for differences in diet, body size, and absorption.

Remember that no regulator verifies label claims before a supplement is sold in most countries, which is why independent testing matters. We return to this point in the quality sections.

Mechanisms of Action of Omega-3 Fatty Acids

Omega-3 fatty acids act through several overlapping mechanisms, which helps explain why they affect many body systems.

1. Membrane incorporation. EPA and DHA are built into the phospholipids of cell membranes, where they displace some arachidonic acid and alter fluidity, thickness, and lipid raft organization. DHA is especially abundant in brain synapses and in the retina's photoreceptors, where it supports signaling and visual function. Altered membrane structure may change how receptors, ion channels, and enzymes behave.

2. Eicosanoid balance. Arachidonic acid is converted by cyclooxygenase and lipoxygenase enzymes into strongly pro-inflammatory and pro-clotting molecules. EPA competes for the same enzymes and produces weaker 3-series prostaglandins and thromboxanes, and 5-series leukotrienes. The net result is a shift away from intense inflammation and platelet aggregation (Calder, 2017).

3. Specialized pro-resolving mediators. EPA and DHA are precursors to resolvins, protectins, and maresins, which actively switch off inflammation and promote healing rather than only blocking it (Serhan, 2014).

4. Receptor and gene signaling. Free long-chain omega-3s activate GPR120 (also called FFAR4), a receptor that reduces macrophage inflammation and improves insulin sensitivity in animal studies (Oh et al., 2010). They also bind PPAR-alpha and PPAR-gamma, nuclear receptors that increase fat burning and reduce inflammatory gene expression, and they reduce activation of the pro-inflammatory transcription factor NF-kappa B.

5. Triglyceride lowering. The best-understood clinical effect arises because omega-3s suppress SREBP-1c, a regulator of fat synthesis in the liver, and raise fat oxidation. They reduce the liver's production of VLDL particles and improve clearance of triglyceride-rich particles by lipoprotein lipase (Jump, 2011; Skulas-Ray et al., 2019).

6. Cardiac and vascular effects. Experimental data suggest that omega-3s can stabilize cardiac cell membranes, modulate ion channels, improve endothelial function through nitric oxide, and slightly reduce blood pressure and heart rate. Interestingly, higher doses are linked to atrial fibrillation in clinical trials, so not every cardiac effect is beneficial.

7. Brain and eye development. DHA enters the brain through a dedicated transporter called MFSD2A, which carries DHA attached to lysophosphatidylcholine across the blood-brain barrier (Nguyen et al., 2014). Once there, DHA supports membrane function, neurogenesis, and neuroprotective signaling.

It is important to stress that most of these mechanisms are demonstrated in cells and animals. They explain how omega-3s could work, but whether each mechanism produces a measurable benefit at supplement doses in people is exactly what clinical trials test.

Pharmacokinetics of EPA and DHA

Pharmacokinetics describes what the body does with a nutrient after it is swallowed. For omega-3 fatty acids, the key steps are as follows.

Digestion and absorption. In the small intestine, pancreatic lipase splits dietary triglycerides into free fatty acids and 2-monoacylglycerol, which are absorbed by intestinal cells. Ethyl esters require a different, slower enzymatic step. Absorbed omega-3s are rebuilt into triglycerides, packed into chylomicrons, and released into the lymph, then the blood (Arterburn et al., 2006).

Distribution. Lipoprotein lipase on blood vessel walls releases fatty acids from chylomicrons so tissues can take them up. Omega-3s then appear in plasma phospholipids, cholesteryl esters, and triglycerides, and in the membranes of red cells, platelets, heart, brain, and other tissues. DHA is selectively retained in the brain and retina.

Time course. Plasma EPA and DHA rise within hours and fall again over days, but incorporation into cell membranes is slower. Red blood cell levels follow the lifespan of the cell, about 120 days, which is why the Omega-3 Index typically needs several months of consistent intake to reach a new steady state.

Metabolism. Most of the omega-3 consumed is used for energy by beta-oxidation, with the rest incorporated into tissues or turned into lipid mediators. A small fraction of ALA is elongated and desaturated into EPA and DHA. Studies suggest that about 5 to 10 percent of ALA becomes EPA and less than 5 percent becomes DHA, with women converting somewhat more than men, probably because of estrogen (Brenna et al., 2009). Conversion is further reduced by high omega-6 intake and by some genetic variants in the FADS gene cluster. Retroconversion of DHA back to EPA occurs only to a small degree.

Elimination. Omega-3s are not excreted unchanged in meaningful amounts. They are oxidized and exhaled as carbon dioxide, or recycled into other lipids.

Bioavailability of Omega-3 Supplements and Fish Oil

Bioavailability describes how much of the dose actually reaches the blood and tissues. Several factors matter.

Chemical form. A crossover study that compared marine omega-3 formulations reported that re-esterified triglycerides were absorbed about as well as or better than natural triglycerides, while ethyl esters were absorbed less well, at roughly 70 percent of the reference (Dyerberg et al., 2010). Free fatty acid forms are absorbed well even when fat intake is low. In practice, differences between forms are real, but they shrink when the supplement is taken with a meal that contains fat.

Co-ingested fat. The strongest practical factor is taking omega-3 with food. Classic work showed that absorption of fish oil fatty acids was clearly higher with a higher-fat meal than with a low-fat one (Lawson and Hughes, 1988).

Phospholipid vs. triglyceride. Krill oil delivers omega-3s as phospholipids, and marketing often claims superior absorption. A direct comparison of krill oil and fish oil found similar incorporation of EPA and DHA into plasma phospholipids when equal amounts were given (Schuchardt et al., 2011). Other studies report differences in some measures, and the question remains open.

Delivery technology. Emulsified oils, self-emulsifying delivery systems, and micellized products can increase absorption in people who take them without food, and some products show several-fold higher short-term blood levels. Whether that translates into better long-term outcomes is not yet established.

Individual factors. Age, gut and pancreatic function, body mass, genetics, baseline omega-3 status, and dosing frequency all influence response. People with fat malabsorption, for example, may need different forms.

A fair summary is that dose and consistency matter more than the brand of form. A modest product taken daily with meals will usually outperform an expensive product taken sporadically on an empty stomach.

Preclinical Evidence Summary for Omega-3 Fatty Acids

Laboratory and animal research forms the foundation of omega-3 science and generates most hypotheses.

• Deficiency studies. Infant rhesus monkeys fed diets low in omega-3 developed visual abnormalities and altered behavior, and rodent studies show impaired brain development and learning when omega-3 is lacking during gestation (Neuringer et al., 1984). These findings underpin recommendations for DHA in pregnancy and infancy.
• Cardiovascular models. In animal models, EPA and DHA reduce triglycerides, limit plaque inflammation, and lower the risk of arrhythmias after ischemia.
• Inflammation and immunity. Cell and animal studies show lower production of inflammatory cytokines, altered macrophage polarization, and increased resolution mediators.
• Genetic models. The fat-1 transgenic mouse, which can convert omega-6 to omega-3 fatty acids on its own, is protected from several inflammatory, metabolic, and cancer-related conditions, which supports a causal role for omega-3 status (Kang et al., 2004).
• Neurological and mood models. Omega-3s show neuroprotective, anti-inflammatory, and neuroplasticity-promoting effects in rodent models of brain injury, neurodegeneration, and depression.
• Metabolic and liver models. Omega-3s reduce liver fat and improve insulin signaling in several animal models.

Three limits apply. First, animals metabolize fats differently from people. Second, doses given to rodents are often much higher than human equivalents. Third, laboratory models often start from a state of omega-3 deficiency, which is less common in people eating adequate fish. For these reasons, positive preclinical findings should be seen as signals that deserve testing, not as proof of benefit in humans.

Human Clinical Evidence Summary for EPA and DHA

Human evidence includes observational studies, which show associations, and randomized controlled trials (RCTs), which test cause and effect. The two sometimes disagree, because people who eat more fish also tend to have healthier lifestyles overall.

Triglycerides. This is the most solid result. Prescription-level doses of 2 to 4 grams per day typically lower triglycerides by about 20 to 30 percent, with larger reductions in people who start with very high levels (Skulas-Ray et al., 2019).

Cardiovascular events. The picture is mixed and depends on dose, formulation, and population.

• GISSI-Prevenzione (1999), using about 1 g per day of mixed EPA and DHA after a heart attack, found a modest reduction in a composite of death, non-fatal heart attack, and stroke.
• JELIS (2007) added 1.8 g per day of EPA to statin therapy in Japanese patients and reported a 19 percent relative reduction in major coronary events (Yokoyama et al., 2007).
• REDUCE-IT (2019) tested 4 g per day of icosapent ethyl in high-risk patients with elevated triglycerides on statins and found a 25 percent relative reduction in major cardiovascular events (Bhatt et al., 2019).
• STRENGTH (2020) tested 4 g per day of a mixed EPA and DHA product in a similar population and was stopped early for lack of benefit (Nicholls et al., 2020).
• VITAL (2019) and ASCEND (2018) tested about 1 g per day in large primary prevention populations. VITAL did not reach its main endpoint, although heart attack risk was lower in a secondary analysis, and ASCEND found no significant reduction in serious vascular events among people with diabetes (Manson et al., 2019; ASCEND Study Collaborative Group, 2018).
• Meta-analyses. A Cochrane review concluded that omega-3 supplements probably have little or no effect on all-cause mortality and cardiovascular events (Abdelhamid et al., 2018), while a meta-analysis of 13 trials with more than 127,000 participants found modest reductions in heart attack and coronary death (Hu et al., 2019).

Why do the trials disagree? Possible reasons include differences in EPA versus DHA content, dose, the placebo oil used, background statin use, baseline fish intake, and the patient population. The question of whether EPA-only products work differently from mixed products is still unresolved.

Atrial fibrillation. A meta-analysis of randomized trials found a higher risk of atrial fibrillation with omega-3 supplementation, with a steeper increase above 1 g per day (Gencer et al., 2021).

Blood pressure. Small average reductions occur, larger in people with hypertension (Miller et al., 2014).

Pregnancy. A Cochrane review found that omega-3 supplementation in pregnancy reduced preterm birth before 37 weeks by about 11 percent and before 34 weeks by about 42 percent, which is a clinically useful finding (Middleton et al., 2018).

Depression. Meta-analyses suggest a small overall benefit, concentrated in formulations with a higher proportion of EPA (Mocking et al., 2016; Liao et al., 2019).

Joint pain. In rheumatoid arthritis, omega-3 supplements reduce pain, morning stiffness, and the need for anti-inflammatory drugs after at least three months (Goldberg and Katz, 2007).

Eye health. Trials did not show that omega-3 slows progression of age-related macular degeneration (AREDS2 Research Group, 2013), and a large dry eye trial found no benefit over an olive oil placebo (Asbell et al., 2018).

Cognition. Trials in older adults without dementia found no clear benefit for preventing cognitive decline (Sydenham et al., 2012).

Evidence Grading by Outcome for Omega-3 Supplements

The table below summarizes our evidence grading, which reflects trial quality, consistency, and size. It is an editorial summary and not an official guideline.

Outcome	Evidence grade	Short interpretation
Lowering of triglycerides	Strong	Reliable at 2 to 4 g EPA and DHA per day
Cardiovascular events in high-risk patients on statins	Moderate	Benefit shown with high-dose purified EPA; not replicated with mixed EPA and DHA
Cardiovascular events in general population	Low to moderate	Small or no benefit at about 1 g per day
Atrial fibrillation risk (harm)	Moderate	Higher risk, especially above 1 g per day
Blood pressure	Moderate	Small reduction, mainly in hypertension
Preterm birth prevention	Moderate to strong	Reduced risk in a Cochrane review
Rheumatoid arthritis symptoms	Low to moderate	Modest pain relief; small trials
Depression	Low to moderate	Small benefit, EPA-predominant products
Infant brain and visual development	Low to moderate	Inconsistent results across trials
Dementia and cognitive decline prevention	Low	No clear benefit in most trials
Age-related macular degeneration	Low	No benefit shown in AREDS2
Dry eye	Low	No benefit over placebo in a large trial
Fatty liver disease	Low to moderate	May reduce liver fat and triglycerides; clinical outcomes uncertain
Cancer prevention	Low	Not supported by current evidence

Dosages Used in Omega-3 Studies

Doses in research vary by goal. The values below are approximate and are drawn from published trial protocols. They describe what was studied, not what any individual should take.

Purpose or trial	Approximate dose per day	Product type
General health (public guidance)	250 to 500 mg EPA and DHA	Diet or supplement
GISSI-Prevenzione	About 850 to 880 mg EPA and DHA	Ethyl ester capsule
VITAL and ASCEND	About 840 mg EPA and DHA (460 mg EPA, 380 mg DHA)	Ethyl ester capsule
AREDS2	About 1,000 mg (650 mg EPA, 350 mg DHA)	Fish oil capsule
JELIS	1,800 mg EPA	Purified EPA ethyl ester
REDUCE-IT	4,000 mg EPA	Icosapent ethyl
STRENGTH	4,000 mg EPA and DHA	Carboxylic acid form
Severe hypertriglyceridemia	2,000 to 4,000 mg	Prescription omega-3
Depression trials	1,000 to 2,000 mg, often EPA-predominant	Capsule
Pregnancy trials	About 600 to 1,000 mg DHA-containing	Capsule

Safety agencies also set upper intake benchmarks. The European Food Safety Authority concluded that long-term supplemental intakes of EPA and DHA combined of up to about 5 g per day appear safe for adults, with up to 1.8 g per day for EPA alone and up to 1 g per day for DHA alone in the populations it examined (EFSA, 2012). The U.S. FDA has affirmed menhaden oil as generally recognized as safe, with a guideline of no more than 3 g per day of EPA and DHA from all sources, of which no more than 2 g from supplements. Higher doses should be used only with medical supervision.

Timing and Use of Omega-3 Supplements

Timing is simpler than most marketing suggests. There is no strong evidence that a particular time of day is better, so the best schedule is the one you can keep.

• Take omega-3 with a meal that contains fat. Absorption improves, and burping and reflux are less likely. For people who take one capsule a day, the largest meal is a sensible choice.
• Split larger doses. Doses above 2 g per day are often divided between two meals to improve tolerance, as in the twice-daily regimen used in REDUCE-IT.
• Be consistent. Because red blood cell levels change slowly, benefits and biomarker changes take weeks to months. Triglyceride reductions usually appear within four to eight weeks, while the Omega-3 Index takes about three to four months to stabilize.
• Protect the product. Store capsules in a cool, dark place, and refrigerate liquids and flaxseed oil after opening. Discard any product with a strong rancid smell.
• Start low if you are sensitive. Beginning with a lower dose for the first week can reduce stomach upset.
• Combine with food sources. Eating oily fish once or twice a week and using supplements for the remainder helps keep intake steady while adding other nutrients such as protein, iodine, and vitamin D.
• Tell your care team. If you take regular medicines, plan surgery, or use high-dose products, discuss timing and dose with a clinician.

Available Forms of Fish Oil and Other Omega-3 Products

Shoppers face a crowded market, and the chemical form is often hidden in small print. The table summarizes the main options.

Form	Source	Main strengths	Main limitations
Natural triglyceride fish oil	Anchovy, sardine, mackerel, and other fish	Familiar, widely studied, lower cost	Lower EPA and DHA concentration per capsule
Ethyl ester concentrate	Fish oil processed with ethanol	High potency; used in most prescription products	Absorbed less well without food; more processing
Re-esterified triglyceride	Fish oil rebuilt from ethyl esters	High potency with triglyceride structure	Higher cost; fewer long-term studies
Free fatty acid	Fish oil	Good absorption even with little dietary fat	Less stable; less common
Krill oil	Antarctic krill	Phospholipid form; astaxanthin; small capsules	Lower dose per capsule; higher price; shellfish allergen
Cod liver oil	Cod liver	Traditional; provides vitamins A and D	Easy to overdose on vitamin A; lower omega-3 content
Algal oil	Microalgae	Vegan; no ocean contaminants; sustainable	Often DHA-dominant; higher price
Flaxseed, chia, and perilla oil	Seeds	Plant-based; supplies ALA	Little conversion to EPA and DHA
Prescription omega-3	Purified fish oil	Standardized, tested, and monitored	Requires a prescription; higher dose and cost
Fortified foods	Eggs, milk, bread, infant formula	Convenient; may improve intake slowly	Added amounts are often small

Softgels, liquids, gummies, chewables, emulsions, and powders all exist. Liquids and emulsions let users adjust doses, but they oxidize quickly once opened. Gummies are popular, yet often supply very small amounts of EPA and DHA, so reading the label is essential. Enteric-coated capsules are designed to reduce burping, although some research suggests the coating may delay absorption.

Safety and Side Effects of Omega-3 Fatty Acids

For most healthy adults, omega-3 fatty acids at typical intakes are well tolerated, and decades of use support a favorable safety profile. Understanding the exceptions matters just as much.

Common effects. The most frequent complaints are fishy aftertaste, burping, heartburn, nausea, and loose stools. These effects usually improve when the supplement is taken with food, divided into smaller doses, stored in the refrigerator, or switched to a different product.

Bleeding. EPA and DHA slightly reduce platelet aggregation. At typical doses, no clear increase in serious bleeding has been shown, but numerically more bleeding events were seen at 4 g per day in REDUCE-IT, and prescribing information advises monitoring in people who take anticoagulants or antiplatelet medicines.

Atrial fibrillation. Trials of higher-dose omega-3 have reported a higher rate of atrial fibrillation than placebo, a finding supported by a meta-analysis (Gencer et al., 2021). The absolute risk is small but real, and people with rhythm disorders should talk to a clinician before using doses above about 1 g per day.

Cholesterol. Products containing DHA can raise LDL cholesterol modestly, especially in people with very high triglycerides, so a lipid panel is typically checked after starting prescription therapy.

Liver enzymes. Prescription labels note that ALT may rise in some patients, and monitoring is advised in people with liver disease.

Vitamin A and D excess. Cod liver oil can supply large amounts of preformed vitamin A. Long-term high intake can be toxic, and it is especially important in pregnancy, so cod liver oil should not be doubled with multivitamins without checking the totals.

Oxidized oil. Rancid products may cause digestive upset, and oxidation products are of concern in animal research, although the human significance is not fully understood. Quality control is therefore a safety topic as well as a performance topic.

Allergy. Refined fish oils contain little protein, so many people with fish allergy tolerate them, but this should be confirmed with an allergist. Krill oil is made from a crustacean, so it is not suitable for people with shellfish allergy.

Upper limits. EFSA concluded that supplemental intakes of EPA and DHA up to about 5 g per day appear safe for adults in the long term, and the U.S. FDA guideline is no more than 3 g per day from all sources (EFSA, 2012). Most people need nowhere near these amounts.

Omega-3 Drug and Supplement Interactions

Most omega-3 interactions are mild, and many are theoretical. The medicines most often discussed are anticoagulants and antiplatelet drugs (because of a possible additive effect on bleeding), blood pressure medicines (because omega-3 lowers pressure slightly), and fat-absorption blockers such as orlistat. Statins and other lipid-lowering drugs are commonly used together with prescription omega-3 on purpose.

Among supplements, high-dose vitamin E, ginkgo, garlic, ginger, and turmeric are sometimes mentioned in relation to platelet function, and cod liver oil adds vitamins A and D to the total intake. Doubling up on several omega-3 products is a common way to exceed a planned dose without noticing.

Because this is a safety topic with several layers, we have published a separate, conservative reference that grades each interaction by strength of evidence, covering drugs, supplements, foods, and laboratory tests [link to the omega-3 interactions page]. As a rule, anyone who takes prescription medicines should show the label of their omega-3 product to a pharmacist before starting.

Special Populations: Who Needs Extra Care With Omega-3

Pregnancy and breastfeeding. DHA is important for fetal brain and eye development, and EFSA suggests about 250 mg of EPA and DHA per day plus an additional 100 to 200 mg of DHA for pregnant and breastfeeding women (EFSA, 2010). Cochrane evidence supports a lower risk of preterm birth with supplementation (Middleton et al., 2018). Pregnant women should choose low-mercury fish, avoid unregulated products, and avoid cod liver oil unless vitamin A levels are known.

Infants and children. DHA is a standard ingredient in many infant formulas, and breast milk DHA reflects the mother's intake. Supplements for children should use age-appropriate doses and be chosen with a pediatrician, as trial results on cognition and behavior are inconsistent.

Older adults. Omega-3 has been studied for heart health, joint pain, and cognition, but the benefits are modest. Older adults often take several medicines, so a medication review is wise.

Vegetarians and vegans. Plant diets supply ALA but little EPA and DHA, and conversion is limited. Algal oil is a direct, vegan source and often the best practical option.

People with cardiovascular disease. Those with very high triglycerides or established heart disease may be offered prescription omega-3, and the dose and product should be managed by a clinician, in light of the atrial fibrillation signal.

People with bleeding disorders, on anticoagulants, or before surgery. Extra care is needed, and the decision to pause supplements before surgery should follow the surgical team's advice.

People with liver disease or fat malabsorption. Metabolism and absorption may differ, and medical guidance is advisable.

People with allergies. Those with fish or shellfish allergy should consider algal oil and speak with an allergist.

Athletes. Omega-3 is popular for recovery and joint comfort, yet results are inconsistent, and food-first approaches are reasonable.

Quality, Testing, and Authentication of Omega-3 Supplements

Because most regulators do not test supplements before sale, quality varies. A study of fish oil products in New Zealand found that most exceeded at least one recommended oxidation limit, and many contained less EPA and DHA than claimed (Albert et al., 2015). Other independent test programs have reported similar issues in various markets, although results differ by country and year.

Several laboratory methods are used to evaluate omega-3 products:

• Gas chromatography with flame ionization detection (GC-FID): The standard method to measure the fatty acid profile and confirm EPA and DHA amounts.
• Peroxide and anisidine values: Classic chemistry tests for primary and secondary oxidation, combined into TOTOX.
• Contaminant testing: Mass spectrometry methods for heavy metals, PCBs, dioxins, and polycyclic aromatic hydrocarbons.
• NMR and isotope methods: Used in advanced laboratories to detect adulteration and confirm the source.
• Sensory evaluation: Trained panels judge odor and taste, because rancid notes can precede measurable chemical change.

For consumers, the most practical steps are to look for independent third-party verification, such as programs from USP, NSF, or IFOS, to check that the label lists EPA and DHA in milligrams, to choose products with an expiry date and a freshness-protecting package, and to smell a capsule if in doubt. Fresh oil should smell mildly of the sea, not sharply fishy or rancid.

Manufacturers who publish certificates of analysis for each batch, adhere to the GOED voluntary monograph, and disclose the source species and form are generally more reliable. The existence of a seal is not a guarantee, so combining several signals gives the best protection.

Adulteration and Contamination Risks in Fish Oil

Two different problems exist: contaminants that come from the environment or processing, and adulteration, which is deliberate or negligent misrepresentation.

Environmental contaminants. Fish accumulate mercury, PCBs, dioxins, pesticides, and other pollutants from their environment. Because these substances are mostly attached to proteins or removed during refining and molecular distillation, properly processed fish oil usually contains far less mercury than whole fish. Unrefined or poorly processed products, including some cold-pressed or crude oils, carry more risk. Arsenic in marine products is largely in organic forms of lower toxicity, but it is still measured.

Oxidation and rancidity. Poor storage or aging produces oxidized oil. This is the most common quality problem and may go unnoticed, particularly in flavored products.

Label inflation and dilution. Some products contain less EPA and DHA than stated, or are diluted with cheaper oils. A label that gives only "total fish oil" without EPA and DHA amounts can hide low potency.

Form misrepresentation. Products may be marketed as natural triglycerides when they are ethyl esters, or the reverse. This affects absorption and cost.

Krill and algal specifics. Krill oil can be mixed with fish oil to raise omega-3 content or reduce price, while the phospholipid content and astaxanthin level vary widely. Algal oil is considered low risk for marine pollutants but should still be tested for oxidation and microbial quality.

Plant oils. Flaxseed oil oxidizes rapidly, and old stock is common on shelves.

Heavy metals and microbial contamination. Lead, cadmium, and microbial counts are controlled in reputable manufacturing, but not all brands test consistently.

Reducing risk is a matter of buying from transparent brands, favoring tested and refined products, storing them correctly, and replacing them when they smell off. People who rely on whole fish should follow public health advice on low-mercury choices, particularly during pregnancy.

Regulatory Overview of Omega-3 Fatty Acids

Regulation varies by country and by how the product is positioned.

United States. Omega-3 dietary supplements fall under the Dietary Supplement Health and Education Act of 1994. Manufacturers are responsible for safety and truthful labeling, and the FDA does not approve supplements before sale. In 2004, the FDA allowed a qualified health claim stating that supportive but not conclusive research shows EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease. Menhaden oil is affirmed as generally recognized as safe within defined limits. Prescription products such as omega-3-acid ethyl esters (approved in 2004) and icosapent ethyl (approved in 2012, with a cardiovascular risk reduction indication added in 2019) are regulated as drugs and are subject to full approval standards.

European Union. Food and supplement claims must be authorized by the European Commission after assessment by EFSA. Authorized claims include a role for EPA and DHA in normal heart function (at 250 mg per day), for DHA in maintaining normal brain function and vision (at 250 mg of DHA per day), and for maintaining normal triglyceride and blood pressure levels at higher intakes. Maternal DHA intake is also linked to normal brain and eye development of the fetus and breastfed infants (EFSA, 2010).

Other regions. Health Canada, Australia's Therapeutic Goods Administration, and agencies in Asia regulate omega-3 products under natural health product or complementary medicine frameworks, usually with quality requirements and claim restrictions.

Global standards. Voluntary monographs from GOED and pharmacopeial monographs from USP and the European Pharmacopoeia define quality limits for oxidation and contaminants. Codex Alimentarius standards cover fish oils for food use.

Because regulations change, readers should verify current rules with the relevant authority before making commercial or clinical decisions.

Research Gaps in Omega-3 Science

Despite thousands of studies, important questions remain open.

1. EPA versus DHA versus mixed products. Trials of purified EPA and trials of mixed EPA and DHA gave different results, but few studies compare them directly.
2. Dose-response and thresholds. It is still unclear whether benefit rises steadily with dose, or whether there is a threshold, and how this balances against the rise in atrial fibrillation risk.
3. Baseline status. Many trials enrolled people with adequate omega-3 intake, which may mask benefits that exist in those with low levels. Using the Omega-3 Index to select participants is a promising approach.
4. Placebo choice. The oil used as a placebo, such as mineral oil or olive oil, may influence results and remains debated.
5. Genetics and individual response. Variants in the FADS and other genes may change how people convert and use omega-3s.
6. Formulation and bioavailability in outcomes. Differences in absorption between forms are measured, but few trials test whether they change clinical outcomes.
7. Brain, mood, and development. Evidence in dementia prevention, depression, and child development is inconsistent and needs larger and better-designed trials.
8. Pro-resolving mediators in humans. The measurement and clinical relevance of these molecules at supplement doses remain uncertain.
9. Long-term safety. Long-term effects of high doses, including rhythm and bleeding outcomes, need continued monitoring.
10. Sustainability. The supply of marine omega-3 for a growing population requires development of algal and engineered crop sources.

FAQ: Omega-3 Fatty Acids, EPA and DHA, and Fish Oil

How much omega-3 should I take each day?

Public health guidance for healthy adults is roughly 250 to 500 mg of combined EPA and DHA per day, often met by eating oily fish twice a week. Higher doses are used under medical supervision for specific conditions such as very high triglycerides.

What is the difference between EPA and DHA?

Both are long-chain omega-3 fatty acids. EPA is more strongly linked to inflammation and cardiovascular research, while DHA is a major structural component of the brain and retina. Many supplements contain both, and some contain mostly one.

Do omega-3 supplements prevent heart attacks?

Evidence is mixed. A high-dose, purified EPA product reduced events in one trial of high-risk patients, while several trials of mixed EPA and DHA at lower doses found little or no benefit in general populations. Omega-3 does reliably lower triglycerides.

Is fish oil better than flaxseed oil?

Fish oil provides EPA and DHA directly, while flaxseed oil provides ALA, which the body converts only in small amounts. For raising EPA and DHA levels, fish oil or algal oil is more effective, although flaxseed has other nutritional value.

Can vegetarians get enough omega-3?

Yes, with planning. Algal oil provides DHA, and sometimes EPA, without fish. Eating ALA-rich foods such as chia, flax, and walnuts is helpful but does not fully replace EPA and DHA.

When is the best time to take omega-3 supplements?

The best time is with a meal that contains fat, because absorption improves and stomach upset is less likely. The specific time of day matters much less than taking it consistently.

Do omega-3 supplements go bad?

Yes. Omega-3 oils oxidize with heat, light, and air. Store them in a cool, dark place, refrigerate liquids, check the expiry date, and discard products that smell rancid.

Is krill oil better than fish oil?

No clear evidence shows that krill oil outperforms fish oil at equal EPA and DHA doses. Krill oil usually supplies less EPA and DHA per capsule and costs more, and it is not suitable for people with shellfish allergy.

Are there side effects of omega-3 supplements?

Most side effects are mild and digestive, such as burping or an aftertaste. At higher doses, there is a possible increase in atrial fibrillation risk, and bleeding should be considered in people on blood thinners. Talk to a clinician if you have any health condition or take prescription medicines.

Key Takeaways and Next Steps

Omega-3 fatty acids are essential structural fats with real, but sometimes overstated, effects. The strongest evidence supports triglyceride lowering and, in some groups, reduced risk of preterm birth and a role in selected high-risk cardiovascular patients. Evidence is weaker or negative for cognition, eye disease, and general cardiovascular prevention. Dose, the ratio of EPA to DHA, product quality, and your own health status all matter, and higher doses carry specific cautions.

To apply this guide, check the EPA and DHA content on any product you use, choose tested and fresh oil, take it with meals, and review your plan with a clinician or pharmacist if you take medicines or have a medical condition. To go deeper, explore our related guides on omega-3 interactions, EPA versus DHA, fish oil dosage, and how to choose a quality supplement [add internal links here]. This page is educational and does not replace personal medical advice.

Scientific References

1. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;7:CD003177.
2. Albert BB, Derraik JGB, Cameron-Smith D, et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015;5:7928.
3. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006;83(6 Suppl):1467S-1476S.
4. AREDS2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005-2015.
5. ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540-1550.
6. Asbell PA, Maguire MG, Pistilli M, et al. n-3 fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018;378(18):1681-1690.
7. Bang HO, Dyerberg J, Hjorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand. 1976;200(1-2):69-73.
8. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.
9. Brenna JT, Salem N Jr, Sinclair AJ, Cunnane SC. Alpha-linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids. 2009;80(2-3):85-91.
10. Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem. 1929;82:345-367.
11. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2(8666):757-761.
12. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105-1115.
13. Dyerberg J, Madsen P, Moller JM, Aardestrup I, Schmidt EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. 2010;83(3):137-141.
14. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on dietary reference values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA J. 2010;8(3):1461.
15. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J. 2012;10(7):2815.
16. Fodor JG, Helis E, Yazdekhasti N, Vohnout B. Fishing for the origins of the "Eskimos and heart disease" story: facts or wishful thinking? Can J Cardiol. 2014;30(8):864-868.
17. Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes. Circulation. 2021;144(25):1981-1990.
18. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction. Lancet. 1999;354(9177):447-455.
19. Global Organization for EPA and DHA Omega-3s (GOED). GOED Voluntary Monograph.
20. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007;129(1-2):210-223.
21. Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39(1):212-220.
22. Holman RT, Johnson SB, Hatch TF. A case of human linolenic acid deficiency involving neurological abnormalities. Am J Clin Nutr. 1982;35(3):617-623.
23. Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127,477 participants. J Am Heart Assoc. 2019;8(19):e013543.
24. Jump DB. Fatty acid regulation of hepatic lipid metabolism. Curr Opin Clin Nutr Metab Care. 2011;14(2):115-120.
25. Kang JX, Wang J, Wu L, Kang ZB. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature. 2004;427(6974):504.
26. Lawson LD, Hughes BG. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem Biophys Res Commun. 1988;152(1):328-335.
27. Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9:190.
28. Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL). N Engl J Med. 2019;380(1):23-32.
29. Middleton P, Gomersall JC, Gould JF, et al. Omega-3 fatty acid addition during pregnancy. Cochrane Database Syst Rev. 2018;11:CD003402.
30. Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids EPA and DHA and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014;27(7):885-896.
31. Mocking RJT, Harmsen I, Assies J, et al. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry. 2016;6:e756.
32. National Institutes of Health, Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals.
33. Neuringer M, Connor WE, Van Petten C, Barstad L. Dietary omega-3 fatty acid deficiency and visual loss in infant rhesus monkeys. J Clin Invest. 1984;73(1):272-276.
34. Nguyen LN, Ma D, Shui G, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. 2014;509(7501):503-506.
35. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268-2280.
36. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687-698.
37. Schuchardt JP, Schneider I, Meyer H, et al. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations: a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis. 2011;10:145.
38. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92-101.
39. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):e673-e691.
40. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 2012;6:CD005379.
41. U.S. Food and Drug Administration. Prescribing information for omega-3-acid ethyl esters (Lovaza) and icosapent ethyl (Vascepa); Qualified health claim for EPA and DHA omega-3 fatty acids and coronary heart disease (2004); 21 CFR 184.1472 (menhaden oil).
42. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS). Lancet. 2007;369(9567):1090-1098.